Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

CSF GAG non-reducing ends in MPS IH after peripheral and brain-penetrating therapies: A model comparing IV non-targeted ERT and HCT.

Molecular therapy. Advances·2026

Same author

HLA-DR expression at diagnosis is not predictive of relapse risk post allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

Haematologica·2026

Same author

Tracking Cytopenias in <i>FANCA</i>-deficient Fanconi Anemia.

medRxiv : the preprint server for health sciences·2025

Same author

Acute Toxicities and Early Outcomes of Tandem Autologous Stem Cell Transplantation in Pediatric High-Risk Neuroblastoma: A Multicenter Study.

Transplantation and cellular therapy·2025

Same author

Opportunities and Challenges With CAR T-cell Treatment of Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia: Review and Recommendations From the Westhafen Intercontinental Group.

Transplantation and cellular therapy·2025

Same author

BRCA1-, BRCA2-, and PALB2-related Fanconi anemia: Scope to expand disease phenotypic features and predict breast cancer risk in heterozygotes.

American journal of human genetics·2025

Search research articles

Related Experiment Video

Updated: Jul 9, 2026

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Recent developments in cell-based immune therapy for neuroblastoma.

Michael R Verneris¹, John E Wagner

¹Blood and Marrow Transplant Program, Department of Pediatrics, University of Minnesota, Mayo Mail Code 366, 420 Delaware Street, S.E., Minneapolis, MN 55455, USA. verneris@umn.edu

Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology

|November 28, 2007

Summary

Neuroblastoma (NB), a childhood cancer, has poor outcomes with standard treatments. Cellular immunotherapies like natural killer cells and T cells show promise for advanced or recurrent NB.

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Related Experiment Videos

Last Updated: Jul 9, 2026

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Area of Science:

Pediatric Oncology
Immunotherapy
Cancer Research

Background:

Neuroblastoma (NB) is a prevalent and aggressive pediatric cancer.
Conventional treatments (chemotherapy, surgery, radiation) yield suboptimal results for advanced NB.
Immune-based therapies offer a promising avenue for recurrent or advanced NB.

Discussion:

Review of preclinical studies and early-phase clinical trials for cellular therapies in NB.
Evaluation of various cellular approaches including natural killer (NK) cells, gammadelta T cells, chimeric antigen receptor (CAR) T cells, dendritic cells, and allogeneic hematopoietic stem cell transplantation (HSCT).

Key Insights:

Cellular immunotherapies are being actively investigated for neuroblastoma treatment.
Diverse cellular platforms demonstrate potential in preclinical and early clinical settings.
These approaches aim to overcome limitations of traditional therapies for high-risk NB.

Outlook:

Further clinical development of cellular therapies is warranted for neuroblastoma.
Optimizing these immunotherapeutic strategies could improve outcomes for affected children.
Integration of cellular therapies into NB treatment protocols may enhance efficacy.